Jan 23, 2024 • 8:00 am EST Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU
Jan 9, 2024 • 8:00 am EST Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)
Dec 18, 2023 • 8:00 am EST Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU
Nov 7, 2023 • 8:00 am EST Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Nov 2, 2023 • 8:00 am EDT Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
Oct 17, 2023 • 8:00 am EDT Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023
Oct 16, 2023 • 8:00 am EDT Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701
Oct 3, 2023 • 8:00 am EDT Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
Sep 27, 2023 • 9:05 am EDT Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
Sep 19, 2023 • 8:00 am EDT Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics